Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324355 | 0.88 | PTGES (0.48) | LMNASMN1; SMN2HTTPTGESALOX5 | |
| SCHEMBL23927507 | 0.86 | HPGD (0.40) | LMNASMN1; SMN2NPSR1HTTTP53 | |
| SCHEMBL15964605 | 0.82 | NPC1 (0.43) | LMNASMN1; SMN2PTGESALOX5HPGD | |
| SCHEMBL30091681 | 0.81 | ALDH1A1 (0.43) | LMNANPSR1HPGDALDH1A1MEN1 | |
| SCHEMBL22272869 | 0.81 | ALDH1A1 (0.43) | LMNANPSR1HPGDALDH1A1MEN1 | |
| SCHEMBL23927492 | 0.81 | ALDH1A1 (0.39) | LMNASMN1; SMN2NPSR1HTTHPGD | |
| SCHEMBL30091560 | 0.80 | CA5A (0.34) | — | |
| SCHEMBL23927463 | 0.80 | MMP13 (0.40) | LMNANPSR1HTTALOX5HPGD | |
| SCHEMBL23927439 | 0.80 | P2RX7 (0.37) | LMNASMN1; SMN2NPSR1HTTTP53 | |
| SCHEMBL30091516 | 0.80 | P2RX7 (0.37) | LMNASMN1; SMN2NPSR1HTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-113166116-B | Amido bridged heterocyclic compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-3901147-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-10-27 | — | — | EP | disclosed |
| CN-113166116-A | Amido bridged heterocyclic compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | RIPK1, RIPK3, RIPK4 | LMNA 2659/4885SMN1; SMN2 1070/4885NPSR1 3694/4885 |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | RIPK1, RIPK3, RIPK4 | LMNA 2659/4885SMN1; SMN2 1070/4885NPSR1 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.